Loading...
Loading...
Browse all stories on DeepNewz
VisitRoche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Markets
Yes • 50%
No • 50%
Roche's official press releases or announcements at medical conferences
No • 50%
Yes • 50%
Roche's financial disclosures or press releases
No • 50%
Yes • 50%
Roche's official press releases or financial reports
Stock remains flat or declines 0-10% • 25%
Stock declines more than 10% • 25%
Stock rises more than 10% • 25%
Stock rises 0-10% • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Contributes more than 5% to revenue growth • 25%
No significant contribution • 25%
Contributes less than 2% to revenue growth • 25%
Contributes 2-5% to revenue growth • 25%
Roche's annual financial report for 2025
Focus on other areas • 25%
Focus on cancer treatments • 25%
Focus on genetic engineering • 25%
Focus on both equally • 25%
Roche's strategic announcements and press releases